Cormorant Asset Management’s SpringWorks Therapeutics SWTX Stock Holding History

Cormorant Asset Management’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-475,000	Closed	-$11.7M	–	80
2022 Q2	$11.7M	Buy	+475,000	New	+$17.4M	0.88%	37
2021 Q3	–	Sell	-15,000	Closed	-$1.24M	–	101
2021 Q2	$1.24M	Sell	15,000 -110,000	-88%	-$8.35M	0.04%	96
2021 Q1	$9.2M	Hold	125,000	–	–	0.2%	74
2020 Q4	$9.06M	Buy	+125,000	New	+$8.05M	0.22%	70

Other funds holding SWTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Cormorant Asset Management's SWTX Position: Q3 2022 in Review

Cormorant Asset Management sold out of SpringWorks Therapeutics (SWTX) in Q3 2022, closing a stake of 475,000 shares — an estimated $11.7M sold.

Cormorant Asset Management first reported a position in SWTX in Q4 2020 and held it in 4 quarters. The position peaked at $11.7M in Q2 2022. 148 funds tracked by Wall St. Rank hold SWTX as of Q3 2022.

Cormorant Asset Management reported no remaining SpringWorks Therapeutics position as of Q3 2022 after selling out during the quarter.
Cormorant Asset Management sold 475,000 SpringWorks Therapeutics shares in Q3 2022, an estimated $11.7M.
Cormorant Asset Management first reported a position in SpringWorks Therapeutics in Q4 2020 and held it in 4 quarters.
Cormorant Asset Management's SpringWorks Therapeutics position peaked at $11.7M in Q2 2022.
148 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2022.

Based on Cormorant Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.